Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent... ORIGINAL ARTICLE Profiling of Oncogenic Driver Events in Lung   Adenocarcinoma Revealed MET Mutation as Independent  Prognostic Factor Sai F. Yeung, BSc,*†‡ Joanna H.M. Tong, PhD,*†‡ Peggy P.W. Law, MPhil,*†‡ Lau Y. Chung, AD,*†‡ Raymond W.M. Lung, PhD,*†‡ Carol Y.K. Tong, MPhil,*†‡ Chit Chow, PhD,*†‡ Anthony W.H. Chan, FRCPA,*†‡ Innes Y.P. Wan, FRCS,§ Tony S.K. Mok, MD,‡¶ and Ka F. To, FRCPA*†‡ Conclusion: Actionable driver events can be detected in two thirds Introduction: Oncogenic driver mutations activating receptor tyro- of lung adenocarcinoma. MET DNA alterations define a subset sine kinase pathways are promising predictive markers for targeted of patients with aggressive diseases that might potentially benefit treatment. We investigated the mutation profile of an updated driver from anti-MET targeted therapy. High negative predictive values of events list on receptor tyrosine kinase/RAS/PI3K axis and the clini- thyroid transcription factor-1 and MET expression suggest poten- copathologic implications in a cohort of never-smoker predominated tial roles as surrogate markers for EGFR and/or MET mutations. Chinese lung adenocarcinoma. Key Words: Lung cancer, EGFR, KRAS, ALK, HER2, BRAF, MET, Methods: We tested 154 lung adenocarcinomas and adenosquamous ROS1, RIT1, TTF-1 lung adenocarcinoma, NRAS, Driver mutations, carcinomas for EGFR, KRAS, HER2, BRAF, PIK3CA, MET, NRAS, Oncogenic driver mutation, East Asian lung cancer, MET amplifica- MAP2K1, and RIT1 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor

Journal of Thoracic Oncology , Volume 10 (9) – Sep 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/profiling-of-oncogenic-driver-events-in-lung-adenocarcinoma-revealed-r2Yn1lOK27

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000620
pmid
26098749
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Profiling of Oncogenic Driver Events in Lung   Adenocarcinoma Revealed MET Mutation as Independent  Prognostic Factor Sai F. Yeung, BSc,*†‡ Joanna H.M. Tong, PhD,*†‡ Peggy P.W. Law, MPhil,*†‡ Lau Y. Chung, AD,*†‡ Raymond W.M. Lung, PhD,*†‡ Carol Y.K. Tong, MPhil,*†‡ Chit Chow, PhD,*†‡ Anthony W.H. Chan, FRCPA,*†‡ Innes Y.P. Wan, FRCS,§ Tony S.K. Mok, MD,‡¶ and Ka F. To, FRCPA*†‡ Conclusion: Actionable driver events can be detected in two thirds Introduction: Oncogenic driver mutations activating receptor tyro- of lung adenocarcinoma. MET DNA alterations define a subset sine kinase pathways are promising predictive markers for targeted of patients with aggressive diseases that might potentially benefit treatment. We investigated the mutation profile of an updated driver from anti-MET targeted therapy. High negative predictive values of events list on receptor tyrosine kinase/RAS/PI3K axis and the clini- thyroid transcription factor-1 and MET expression suggest poten- copathologic implications in a cohort of never-smoker predominated tial roles as surrogate markers for EGFR and/or MET mutations. Chinese lung adenocarcinoma. Key Words: Lung cancer, EGFR, KRAS, ALK, HER2, BRAF, MET, Methods: We tested 154 lung adenocarcinomas and adenosquamous ROS1, RIT1, TTF-1 lung adenocarcinoma, NRAS, Driver mutations, carcinomas for EGFR, KRAS, HER2, BRAF, PIK3CA, MET, NRAS, Oncogenic driver mutation, East Asian lung cancer, MET amplifica- MAP2K1, and RIT1

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2015

References